Group items tagged

Surface disinfectants are chemical formulations that eliminate microorganisms from surfaces or significantly decrease the possibility of their transfer through hand contact between surfaces. These include bedside tables, chairs, walls, floors, and medical equipment (clinical contact surfaces). The global surface disinfectant market is expected to reach USD 789.1 Million by 2022 from USD 529.6 Million in 2017, at a CAGR of 8.3%. Increasing number of surgical procedures, rising geriatric population, and subsequent growth in the prevalence of chronic diseases are the major driving factors for this market.

The Market Research on Vascular Graft, By Considering useful aspects like; Material, Product, Application, End User - Global Future Forecast till 2023, published by MarketsandMarkets™, the report studies the global Vascular Graft market over the forecast period of 2017 to 2023. The market is projected to reach USD 3.80 Billion by 2023 at a CAGR of 7.3%.

Vascular Graft market Research describing the professional information and in-depth study on the current state of the world market along with competitive analysis. Vascular Graft exploring the market size, trend, revenue and forecasts up to 2023. This report is a valuable source of guidance for companies and individuals offering Industry Chain Structure, Business Strategies, and Proposals for New Project Investments.

The Market Research on Wound Debridement, By Considering useful aspects like; Material, Product, Application, End User (Hospital, ASCs) - Global Future Forecast till 2023, published by MarketsandMarkets™, the report studies the global Wound Debridement market over the forecast period of 2017 to 2023. The market is projected to reach USD 1,041.0 Million by 2023 at a CAGR of 8.2%.

The Global Wound Debridement Market Research Report 2018 gives an in-depth valuation of the Wound Debridement that includes technologies, key trends, market share, size, challenges, opportunities, future forecast, value chain, and strategies. The Research report gives a complete overview of the market and contains a Future trend, Current Growth Factors. The study is segmented by products type, application/end-users.

Biological Safety Cabinet Research reports cover detailed competitive outlook including the market share and company profiles of the key participants operating in the Global market. The Biological Safety Cabinet market report provides an in-depth overview of Product Specification, technology, product type and production Analysis considering major factors such as Revenue, Cost, Gross and Gross Margin

Today, pharmaceutical companies can't simply make an effective drug and count on healthcare providers (HCPs) to come to them - they have to find innovative ways to attract them. Statista shows that in 2015 there were only 3,286 pharma companies with active research and development pipelines. In 2023, this number jumped to more than 5,500. As an earth-shattering number of new drugs are flooding the market each year, HCPs are having a hard time determining the best medicine for their patients. Meanwhile, pharma companies invest more in marketing to help HCPs get rid of choice paralysis and make them choose their solution over that of competitors. In this article, we will share the tried-and-true tactics to build a strong pharma brand. Get creative with interactive email marketing One…two…three…No, we're not counting to run a marathon. Three seconds is what you've got to pull your reader in with your email. Fail to quickly grab the audience's attention? We've got some bad news for you. Nobody's going to bother reading about how amazing your pharmaceutical product is if you're churning out generic emails with artificial intelligence tools.

The Medicines and Healthcare products Regulatory Agency (MHRA) has introduced a new tool to check the eligibility for marketing authorisation applicants. Applicants are now required to use the online 'Eligibility Checker' tool to determine whether their Marketing Authorisation Application (MAA) is suitable for the Agency's International Recognition procedure (IRP), which will become operational on 1 January 2024. The tool will also help applicants identify which route (A or B) to follow, before submitting their IRP application. Julian Beach, MHRA Interim Executive Director of Healthcare Quality and Access, said that the tool has been tailored to "facilitate a smooth and efficient process for marketing authorisation applicants."

The protein labeling market is expected to reach USD 1,894.5 Million by 2020 from USD 1,089.5 Million in 2015, growing at a CAGR of 11.7% from 2015 to 2020. A strong trend of increasing healthcare expenditure will majorly drive the growth of the market. Other growth factors include increasing R&D spending and growth in proteomics research. The increasing use of protein labeling in in vitro labeling, in vivo labeling, and bioorthogonal labeling methods will provide opportunities for market growth.

market is expected to witness rapid growth owing to the increasing number of breast cancer surgeries and implementation of favorable reimbursement guidelines for localization devices. However, uncertainty in regulatory approval procedures due to risks associated with breast lesion localization devices is expected to restrain the growth of this market.

Vascular Graft market Research describing the professional information and in-depth study on the current state of the world market along with competitive analysis. Vascular Graft exploring the market size, trend, revenue and forecasts up to 2023. This report is a valuable source of guidance for companies and individuals offering Industry Chain Structure, Business Strategies, and Proposals for New Project Investments.

he global multiplex assays market is projected to reach USD 3.35 Billion in 2023 from USD 2.33 Billion in 2018, at CAGR of 7.5%. Multiplex assays enables the simultaneous detection of multiple analytes in a single run/cycle of the assay. The use of multiplex assays in companion diagnostics for increasing the safety & efficacy of therapies and the advantages of multiplex assays over conventional singleplex assays are driving the growth of the market.

The global market for chronic kidney disease drugs is expected to witness single-digit growth during 2019-2025. The drug pipeline of chronic kidney disease looks promising with novel therapeutic approaches, such as cell therapy, likely to enhance the market growth opportunities. However, the competition from biosimilars and complex drug development processes are impeding the market growth. Over the period, extensive research is being done to fill the unmet needs' gap. The advances in the arena of regenerative treatment have come up with budding advancement of cell therapies that help regeneration and repairing of the kidneys. Cell therapy is proficient of refining the fundamental functioning capability of the kidney. Uncontrolled high blood pressure and diabetes are the leading causes of kidney failure globally.

Covid-19 vaccine makers are shifting gears and planning for a smaller, more competitive booster shot market after delivering as many doses as fast as they could over the last 18 months. Executives at the biggest Covid vaccine makers including Pfizer and Moderna said they believe most people who wanted to get vaccinated against Covid have already done so - more than five billion people worldwide. In the coming year, most Covid vaccinations will be booster shots, or first inoculations for children, which are still gaining regulatory approvals around the world, they said. Pfizer, which makes its shot with Germany's BioNTech and Moderna still see a major role for themselves in the vaccine market even as overall demand declines. Upstart US vaccine maker Novavax and Germany's CureVac, which is working with GlaxoSmithKline, are developing vaccines they hope to target at the booster market. The roles of AstraZeneca and Johnson & Johnson, whose shots have been less popular or effective, are expected to decline in this market.

Boots witnessed a 'record-breaking' performance for beauty driving retail sales with a growth of 16 per cent in the three months to 28 February 2023. The beauty category delivered a record January, and premium beauty saw its biggest ever sales week in December. Skincare reported three consecutive weeks of record sales in December driven by the 'expert skincare' category in which brands including No7, La Roche-Posay, CeraVe and Eucerin proved popular. Boots beauty transformation strategy continued with 19 new beauty halls opened in Q2 and the 170th store to receive a beauty makeover opening at Westfield White City post-period end. Boots now stocks over 500 big name and cult beauty brands and exclusively sells the UK's leading skincare brand, No7. The business reported its eighth consecutive quarter of market share growth with gains across all categories, led by beauty - the stand-out performer of the quarter. Footfall, basket size and the number of Advantage Card customers all increased, as more people chose to shop at Boots. The Christmas period was particularly strong with retail sales in the five weeks to 31 December up 17.4% and outperforming the market. Boots further expanded its value offering in the quarter, announcing its biggest ever savings as part of its continued focus on the affordability of life's essentials. This included the addition of 60 new products to the Boots Everyday label as well as the extension of its Price Advantage scheme, which has to date resulted in £30 million of customer savings and now includes discounts on over 800 products every month.

Covid-19 vaccine maker Novavax on Wednesday said it expects revenue this year to be flat or lower as it works to improve its commercial performance and pick up market share from much larger rivals, Pfizer and Moderna. The company posted a larger-than-expected fourth-quarter loss as revenue lagged analysts' estimates. Chief executive John Jacobs said Novavax claimed just a low-single-digit percentage market share in the US during the most recent vaccination campaign, as demand for Covid vaccines was smaller than hoped and the company got its protein-based shot to market later than its messenger RNA-based rivals. "We were disappointed with that US performance," Jacobs said in an interview. He said the company's sales force was not targeted enough toward retail pharmacy chains, and that its 5-dose vials were not as convenient for use as rivals' pre-filled syringes.

The clinical decision support systems market is projected to reach USD 1,752.0 Million by 2023 from USD 901.0 Million in 2017, at a CAGR of 11.8%. Factors such as government support & initiatives, growing incidence of medication errors, rising prominence & usage of big data and mhealth tools, high returns on investment for CDSS solutions, and growing adoption of cloud computing in healthcare are driving the growth of this market.

The global remote patient monitoring system market size is expected to expand at a CAGR of 19.7% from 2021 to 2028.

Global drug discovery services market will continue to grow, owing to upsurge in externalization of R&D activities, rising expenditure on R&D, and increasing incidence of chronic diseases. Expiration of patents boosting the demand for drug discovery and the introduction of innovative drug discovery technologies are projected to support the market growth during the forecast period 2019-2025. The global drug discovery services market, by type, is segmented into medicinal chemistry services, biology services, and pharmacokinetics and drug metabolism. Among these, the medicinal chemistry services segment accounted for the largest share in 2018 and is expected to grow at a high-double-digit CAGR by 2025. Increasing tendency of pharma companies to externalize discovery & development services, upsurge in the number of drug discovery & development activities, and growing R&D expenditure are the key factors driving the growth of the segment.

Antiviral Drugs Market by Mechanism of Action (Nucleotide Polymerase Inhibitors, Reverse Transcriptase Inhibitors, and Protease Inhibitors), Type (Generic Drugs and Branded Drugs), and Application (HIV, Hepatitis, Herpes, and Influenza) - Global Opportunity Analysis and Industry Forecast, 2018-2025